Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology
2015
ABSTRACT Over the past decade, basic and
translational researchdelivered comprehensive evidence for the relevance of the Ca2+-binding protein S100A1 in cardiovascular diseases. Aberrant expression levels of S100A1 surfaced as molecular key defects, driving the pathogenesis of chronic heart failure, arterial and pulmonary hypertension, peripheral artery disease and disturbed myocardial infarction healing. Loss of intracellular S100A1 renders entire Ca2+-
controlled networksdysfunctional, thereby leading to cardiomyocyte failure and
endothelial dysfunction. Lack of S100A1 release in ischemic myocardium compromises cardiac fibroblast function, entailing impaired damage healing. This review focuses on
molecular pathwaysand
signaling cascadesregulated by S100A1 in cardiomyocytes, endothelial cells and cardiac fibroblasts in order to provide an overview of our current mechanistic understanding of S100A1's action in cardiovascular pathophysiology.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
63
References
15
Citations
NaN
KQI